Asterias Biotherapeutics Inc Class A
(NYSE Amex Equities : AST)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.34%93.981.3%$970.65m
BIIBBiogen Inc.
-0.76%225.451.3%$898.03m
GILDGilead Sciences, Inc.
-0.85%62.710.9%$410.71m
AMGNAmgen Inc.
-2.51%177.891.2%$409.40m
ILMNIllumina, Inc.
-0.13%318.283.5%$277.11m
REGNRegeneron Pharmaceuticals, Inc.
-2.93%332.932.6%$235.48m
VRTXVertex Pharmaceuticals Incorporated
0.46%167.731.9%$221.09m
ONCESpark Therapeutics, Inc.
-0.16%110.5411.2%$169.51m
ALXNAlexion Pharmaceuticals, Inc.
-0.36%125.462.0%$164.75m
EXASExact Sciences Corporation
0.88%92.6225.3%$152.45m
SRPTSarepta Therapeutics, Inc.
-1.84%116.5514.7%$138.78m
AAgilent Technologies, Inc.
1.09%76.251.6%$121.39m
INCYIncyte Corporation
-1.62%73.122.5%$90.48m
IONSIonis Pharmaceuticals, Inc.
-0.37%72.418.3%$88.04m
BMRNBioMarin Pharmaceutical Inc.
0.43%82.704.3%$84.99m

Company Profile

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.